lipoxin a4 has been researched along with Myocardial Infarction in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, R; Chen, Y; Li, J; Li, N; Liu, C; Liu, W; Song, L; Wang, Y; Yan, H; Yan, S; Zhao, H; Zhao, X; Zhou, J; Zhou, P | 1 |
| Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
| Andersson, P; Bratt, J; Cederholm, T; Heimbürger, M; Palmblad, J | 1 |
| Blumberg, N; Lannan, KL; Phipps, RP; Spinelli, SL | 1 |
| Bajaj, M; Birnbaum, Y; Castillo, AC; Ling, S; Perez-Polo, JR; Qian, J; Ye, H; Ye, Y | 2 |
6 other study(ies) available for lipoxin a4 and Myocardial Infarction
| Article | Year |
|---|---|
Prognostic impacts of Lipoxin A4 in patients with acute myocardial infarction: A prospective cohort study.
Topics: Humans; Lipoxins; Myocardial Infarction; Prognosis; Prospective Studies | 2023 |
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |
Inhibition of neutrophil-dependent cytotoxicity for human endothelial cells by ACE inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Cell Adhesion; Cells, Cultured; Cytotoxicity, Immunologic; Enalapril; Human Umbilical Vein Endothelial Cells; Humans; Immunologic Factors; Immunomodulation; Intercellular Adhesion Molecule-1; Lipoxins; Myocardial Infarction; Neutrophils; Receptors, Tumor Necrosis Factor; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2014 |
Maresin 1 induces a novel pro-resolving phenotype in human platelets.
Topics: Adaptor Proteins, Signal Transducing; Blood Platelets; Cardiovascular Diseases; Docosahexaenoic Acids; Hemostasis; Humans; Inflammation; Lipoxins; Myocardial Infarction; Phenotype; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, G-Protein-Coupled | 2017 |
Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.
Topics: Animals; Blood Glucose; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Immunoblotting; Lipids; Lipoxins; Male; Membrane Proteins; Mice; Myocardial Infarction; Myocardium; Phosphodiesterase 3 Inhibitors; PTEN Phosphohydrolase; Tetrazoles; Triazoles | 2012 |
Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes.
Topics: Animals; Blood Glucose; Blotting, Western; Cholesterol; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme Activation; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Hypoglycemic Agents; Isoquinolines; Lipoxins; Male; Mice; Myocardial Infarction; Myocardium; Peptides; Phosphodiesterase 3 Inhibitors; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Receptors, Glucagon; Signal Transduction; Sulfonamides; Tetrazoles; Triglycerides; Up-Regulation; Venoms | 2013 |